xCures announces collaboration with CancerCompass to better support patients and caregivers through their cancer journey
Today, xCures announced their collaboration with CancerCompass, allowing consumers who contact CancerCompass to access the xCures’ platform and services. “xCures partnering with CancerCompass is a significant step toward improving access to personalized knowledge about advanced cancer treatment options,” stated Mika Newton, xCures’ CEO. “This is important progress in our mission to broaden the availability of […]
xCures Joins Decentralized Trials & Research Alliance (DTRA) to Democratize and Accelerate Clinical Trials
New Global Industry Coalition Aims to Dramatically Increase Access for All Patients Populations in Clinical Trials and Research December 23, 2020 – xCures joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research. The “Decentralized Trials & Research Alliance (DTRA),” […]
xCures launches xACCESS – A new module in their AI-assisted clinical platform
The new registration module facilitates expanded access to novel therapies for patients with advanced cancer while accelerating the generation of real-world data on safety and efficacy. SAN FRANCISCO, CA, NOVEMBER 17. Today, xCures Inc. is launching xACCESS – a new registration module for their AI-assisted clinical study platform. The module is used to enroll cancer […]
xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)
BioMed Valley Discoveries’ first-in-class ERK inhibitor available through newly opened compassionate use protocol. September 28, 2020 – San Francisco, CA. – xCures, a clinical study platform provider, announces the US Food and Drug Administration (FDA) granted their IND for an intermediate Expanded Access Program (EAP) for the ERK inhibitor ulixertinib (BVD-523). Ulixertinib is being developed by […]
xCures together with Cancer Commons and a confidential partner, to launch a virtual medical food trial in patients with pancreatic cancer
San Francisco, CA, September 23, 2020. Today, xCures Inc., together with a confidential partner, is pleased to announce their launch of a medical food clinical trial. This study, to be led by Jennifer R. Grandis, M.D., aims to characterize a highly engineered medical food formulation as a foundation or component for treatment of patients with […]
BEAT19 crowd-sourcing study jump starts data collection for research to find effective treatments in battle against COVID-19
– 240 million Americans can play a vital role in the search for a vaccine or treatment by contributing critical data from home – SAN FRANCISCO – April 15, 2020 – xCures, a health technology company focused on the use of artificial intelligence, has released preliminary data from the company’s Behavior, Environment, And Treatments for […]
Oncology Pioneer xCures Names Experts to Advisory Boards
Prominence of Scientific and company Advisory Board signals attraction to xCures’ novel patient-centric approach to treatment and continuous learning for cancer LOS ALTOS, CA, USA, October 10, 2019 — Today, xCures Inc. announced the appointment of members to its Scientific Advisory Board (SAB) and company Advisory Board. The SAB supports the work of xCures’ Virtual […]
Integrating Clinical Research And Care In A Perpetual Trial
With attention focused on the difficulties associated with traditional oncologic clinical trials, xCures’ Perpetual Trial and the potential for a Real World Data-based learning ecosystem has gained attention. Recently, Diagnostic World News interviewed xCures CEO Mika Newton about Perpetual Trials, AI, and the future of accelerating treatment and knowledge in the development of cancer treatments. To […]
Oncology Expert Keith T. Flaherty, MD Named Chairman of xCures Scientific Advisory Board
Keith T. Flaherty, MD, has joined the xCures Scientific Advisory Board as Chairman. The Scientific Advisory Board supports the work of xCures’ Virtual Tumor Boards in running patient-centered “Perpetual Trials” for oncology. xCures currently runs XCELSIOR, a Perpetual Trial integrating real-world data and patient-reported outcomes with an AI-enhanced Virtual Tumor Board. By implementing this precision […]
xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-Mutant Gliomas
LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded Access to ONC201 […]